NCT03568058 — Aaron Miller cancer immunotherapy trial
Personalized Immunotherapy in Adults With Advanced Cancers Immunotherapy in Adults With Advanced Cancers
Registry record
| Registry ID | NCT03568058 ↗ |
|---|---|
| Lead sponsor | Aaron Miller |
| Collaborators | — |
| Phase | Phase 1 |
| Status | Completed |
| Indication | Advanced Cancer |
| Enrollment | 25 participants |
| Start date | 2018-07-26 |
| Primary completion | 2022-12-12 |
| Last registry update | 24 Mar 2026 |
Every field above is mirrored from the study record on ClinicalTrials.gov (NCT03568058), which the sponsor maintains and which carries the full protocol summary, eligibility criteria, sites and contacts. No neoantigen vaccine is approved anywhere yet — every program here is investigational, and inclusion is not an endorsement. See the methodology for how the tracker is built.
Where this fits
No modality, tumor or player hub covers this study yet. Browse the field map for the axes the daily brief does track.
FAQ
What phase is NCT03568058?
NCT03568058 (Personalized Immunotherapy in Adults With Advanced Cancers Immunotherapy in Adults With Advanced Cancers) is registered on ClinicalTrials.gov as Phase 1, sponsored by Aaron Miller.
Is NCT03568058 recruiting?
As of the 2026-03-24 registry update, NCT03568058 is listed as "Completed". Eligibility criteria, study sites and contacts are maintained by the sponsor on the ClinicalTrials.gov record.
Who is running NCT03568058?
The lead sponsor is Aaron Miller.
What condition does NCT03568058 study?
The registered condition is Advanced Cancer. Primary completion is listed as 2022-12-12.
Are results available for NCT03568058?
neoag.ai mirrors the registry's factual fields — sponsor, phase, status and dates — and does not publish trial results. Any posted results, publications, or outcome measures appear on the ClinicalTrials.gov record for NCT03568058.
Back to the full neoantigen vaccine trial tracker — 107 studies, refreshed daily from ClinicalTrials.gov. Background: primer, glossary, and the companies landscape.